These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 12635459)

  • 21. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
    Bouchard RH; Demers MF; Simoneau I; Alméras N; Villeneuve J; Mottard JP; Cadrin C; Lemieux I; Després JP
    J Clin Psychopharmacol; 2001 Feb; 21(1):110-1. PubMed ID: 11199934
    [No Abstract]   [Full Text] [Related]  

  • 23. Weight gain and antipsychotic medications.
    Aquila R; Emanuel M
    J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperprolactinemia and male sexual dysfunction.
    Dickson RA; Glazer WM
    J Clin Psychiatry; 1999 Feb; 60(2):125. PubMed ID: 10084644
    [No Abstract]   [Full Text] [Related]  

  • 26. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.
    Zito JM
    Psychiatr Clin North Am; 1998 Mar; 21(1):181-202. PubMed ID: 9551496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
    Rabinowitz J; Lichtenberg P; Kaplan Z
    Schizophr Res; 2000 Dec; 46(2-3):91-6. PubMed ID: 11120420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of olanzapine as first-line schizophrenia therapy.
    Cohen LJ
    Am J Health Syst Pharm; 1999 Aug; 56(15):1559-60, 1563-4. PubMed ID: 10478999
    [No Abstract]   [Full Text] [Related]  

  • 31. Olanzapine: an atypical antipsychotic for schizophrenia.
    Lund BC; Perry PJ
    Expert Opin Pharmacother; 2000 Jan; 1(2):305-23. PubMed ID: 11249551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
    Verma S; Orengo CA; Kunik ME; Hale D; Molinari VA
    Int J Geriatr Psychiatry; 2001 Feb; 16(2):223-7. PubMed ID: 11241729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
    Webster D; Devarajan S; Gallant J; Harris A; Kopala LC
    Schizophr Res; 2002 Jul; 56(1-2):187-9. PubMed ID: 12084432
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 35. [Atypical antipsychotics].
    Naber D
    Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
    [No Abstract]   [Full Text] [Related]  

  • 36. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():3-9. PubMed ID: 9766613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and atypical antipsychotics.
    Rudnick A
    J Clin Psychopharmacol; 1998 Oct; 18(5):424-5. PubMed ID: 9790165
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical trial response and dropout rates with olanzapine versus risperidone.
    Santarlasci B; Messori A
    Ann Pharmacother; 2003 Apr; 37(4):556-63. PubMed ID: 12659615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.
    Phan TG; Yu RY; Hersch MI
    Med J Aust; 1998 Aug; 169(4):230-1. PubMed ID: 9734590
    [No Abstract]   [Full Text] [Related]  

  • 40. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
    Aubry JM; Simon AE; Bertschy G
    J Clin Psychiatry; 2000 Sep; 61(9):649-55. PubMed ID: 11030485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.